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Introduction
Acetazolamide-responsive ataxia is a rare hereditary episodic ataxia 
(EA) disorder which is characterized with symptoms of paroxysmal 
cerebellar ataxia. The condition was first described by Parker in 1946 
at the Mayo Clinic in a case series of 11 patients [1]. The patients had 
ataxic episodes with minimal to no symptoms between attacks. Such 
episodes could be brought on by overexertion both physically and 
mentally and trigger attacks.
EA is most commonly treated with a carbonic anhydrase inhi-
bitor, which prevents the interaction of H2O + CO2 1  H2CO3 [2]. 
This inhibition leads to a state of acidosis within the CSF. The re-
duction of pH using acetazolamide, a well-known carbonic anhy-
drase inhibitor, is believed to cause the therapeutic benefits when 
treating episodic ataxia. Studies do show that patients experiencing 
episodic ataxia have an abnormal high cerebellar pH level causing 
regional alkalosis. 
There are several subtypes of EA. While the symptoms remain 
relatively constant throughout all subtypes, it’s the duration and 
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genetic factors that differentiate them. Episodic 
ataxia type 1 (EA1) has been mapped to a specific 
brain channelopathy and shows less of a treatment 
response to acetazolamide, as opposed to episodic 
ataxia type 2 (EA2). Acetazolamide has been used 
as a successful therapy in EA2 for 50% to 75% of 
patients it [3].
Case Report
A 39 year old right-handed Caucasian man with 
EA presented to our neurology clinic. The patient 
has a 10 year history of ataxic spells deemed aceta-
zolamide-responsive ataxia. Episodes tend to reach 
their peak in 10 minutes lasting from 1 hour up to 
4 hours requiring multiple emergency department 
visits. The patient describes that these episodes start 
with numbness and tingling in his feet, progressing 
to his neck and head also associated with light-
headiness, dizziness, blurry vision and sensation of 
heaviness throughout his body, reporting a feeling 
of “drunkenness”. Stumbles while walking and must 
hold onto someone while walking. His wife states 
that his eyes are “jerky” during these episodes, and 
his speech becomes very slurred; although at ba-
seline he does have a speech impediment per his 
wife and father. The patient has no family history 
of any neurological disorders and no one else in his 
family has experienced similar symptoms. Although 
EA is usually hereditary and seen throughout a fa-
mily sporadic cases do appear.
The patient was having episodes on average 
once a week in the winter and 3-4 times a week 
during the summer. The patient reported that 2-3 
years previously he was prescribed acetazolamide 
for his ataxic spells with great relief of symptoms 
in terms of frequency and severity. However, the 
patient discontinued acetazolamide due to dysgeu-
sia, a disorientation of taste often producing a sour 
taste.
On the patient’s initial exam, he showed pro-
minent saccade and nystagmus, however, without 
other cerebellar findings. He was prescribed metha-
zolamide, another carbonic anhydrase inhibitor, at 
50 mg twice a day later up-titrated to 100 mg twice 
a day. He denied dysgeusia while on methazolamide 
and reported efficacy in terms of attacks of ataxia 
even greater than acetazolamide.
Discussion
We present a sporadic case of acetazolamide-res-
ponsive ataxia that was successfully treated with 
methazolamide. Treatment with methazolamide is 
believed to be completely unique and never used 
before in treating EA. The patient was on acetazo-
lamide with good clinical efficacy but discontinued 
due to dysgeusia. This adverse-effect is well pu-
blished. For example, acetazolamide is known to 
be used by hikers to counter the effect of altitude 
sickness. A group of hikers took 500 mg of aceta-
zolamide to ascend between 12,000-14,000 feet 
and reported a change in taste with carbonated 
beverages [4]. 
Treatment with acetazolamide in cases of EA are 
well documented, however, to our knowledge, ne-
ver reported with methazolamide. However, gene-
rally heterocyclic compound such as methazolamide 
are more active then homocyclic compounds such 
as acetazolamide [5]. Maren in his article compa-
ring the pharmacology between methlazolamide 
and acetazolamide states that methazolamide is 
superior in almost all domains. Methazolamide has 
higher rates of diffusion into the tissue with lower 
plasma binding and a longer duration of activity. 
The half-life of methazolamide is 14 hours com-
pared to 5 hours with acetazolamide [5]. Further, 
Maren goes as far as saying “I do not recommend 
acetazolamide for any medical use or any experi-
mental use either” [5].
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Conclusion
We demonstrate the clinical efficacy of methazola-
mide for acetazolamide-responsive ataxia in our pa-
tient. Comparing the effectiveness of acetazolamide 
versus methazolamide in the treatment of EA (and 
other conditions such as glaucoma and idiopathic 
intracranial hypertension) may be warranted.
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